<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ophthalmology</journal-id><journal-title-group><journal-title xml:lang="ru">Офтальмология</journal-title><trans-title-group xml:lang="en"><trans-title>Ophthalmology in Russia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1816-5095</issn><issn pub-type="epub">2500-0845</issn><publisher><publisher-name>Ophthalmology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18008/1816-5095-2024-3-517-526</article-id><article-id custom-type="elpub" pub-id-type="custom">ophthalmology-2429</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Профилактика синдрома сухого глаза перед проведением факоэмульсификации катаракты у пациентов с косметологическими процедурами в периорбитальной зоне в анамнезе</article-title><trans-title-group xml:lang="en"><trans-title>Prevention of Dry Eye Syndrome Before Phacoemulsification of Cataracts in Patients with a History of Cosmetic Procedures in the Periorbital Area</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Трубилин</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Trubilin</surname><given-names>А. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Трубилин Александр Владимирович - кандидат медицинских наук, доцент кафедры офтальмологии.</p><p>Ул. Гамалеи, 15, Москва, 123098</p></bio><bio xml:lang="en"><p>Trubilin Alexander V. - PhD, Associate Professor of the of Ophthalmology department.</p><p>Gamalei str. 15, Moscow, 123098</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8551-0661</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полунина</surname><given-names>Е. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Poluninа</surname><given-names>E. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Полунина Елизавета Геннадьевна - доктор медицинских наук, профессор кафедры офтальмологии.</p><p>Ул. Гамалеи, 15, Москва, 123098</p></bio><bio xml:lang="en"><p>Poluninа Elizabet G. - MD, Professor of the of Ophthalmology Department.</p><p>Gamalei str. 15, Moscow, 123098</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Трубилин</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Trubilin</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Трубилин Владимир Николаевич - доктор медицинских наук, профессор, заведующий кафедрой офтальмологии.</p><p>Ул. Гамалеи, 15, Москва, 123098</p></bio><bio xml:lang="en"><p>Trubilin Vladimir N. - МD, Professor, head of the of Ophthalmology Department.</p><p>Gamalei str. 15, Moscow, 123098</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Закатянский</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Zakatianskii</surname><given-names>V. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Закатянский Владимир Сергеевич – офтальмохирург.</p><p>Проспект Луначарского, 45, корп. 2, Санкт‐Петербург, 194291</p></bio><bio xml:lang="en"><p>Zakatianskii Vladimir S. – ophthalmosurgion.</p><p>Lunacharskogo ave., 45, bld. 2, St. Petersburg, 194291</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Академия постдипломного образования ФГБУ «Федеральный научно-клинический центр» Федерального медико-биологического агентства</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Academy of Postgraduate Education of the Federal State Budgetary Institution Federal Scientific and Practical Center of the Federal Medical and Biological Agency of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ «Ленинградская областная клиническая больница»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Leningrad Regional Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>02</day><month>10</month><year>2024</year></pub-date><volume>21</volume><issue>3</issue><fpage>517</fpage><lpage>526</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Трубилин А.В., Полунина Е.Г., Трубилин В.Н., Закатянский В.С., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Трубилин А.В., Полунина Е.Г., Трубилин В.Н., Закатянский В.С.</copyright-holder><copyright-holder xml:lang="en">Trubilin А.V., Poluninа E.G., Trubilin V.N., Zakatianskii V.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.ophthalmojournal.com/opht/article/view/2429">https://www.ophthalmojournal.com/opht/article/view/2429</self-uri><abstract><p>Факоэмульсификация катаракты в современной офтальмологической практике достигла пика с точки зрения безопасности, прогнозируемости результата и удовлетворенности пациентами полученного результата. В значительной степени изучено влияние синдрома сухого глаза на эффективность данного оперативного вмешательства, однако возникают новые факторы риска, влияющие на развитие синдрома сухого глаза, такие как косметологическое вмешательство в периорбитальной зоне (инъекции ботулотоксина в периорбитальной зоне, наращивание ресниц, блефаропластика). Влияние данных факторов риска развития синдрома сухого глаза (ССГ) на течение послеоперационного периода недостаточно изучено. Важным аспектом при подготовке пациентов к офтальмохирургическому вмешательству, в частности к факоэмульфикации катаракты, которая перешла в разряд, в том числе, рефракционных операций, является стабилизация состояния глазной поверхности и купирование признаков и симптомов ССГ. Материалы и методы. В исследование включены 117 пациентов, которым планировалось проведение факоэмульсификации катаракты. Все 117 пациентов были женского пола для унификации исследования. Первая группа — 85 человек с факторами риска развитая ССГ (ботокс, татуаж, наращивание ресниц, блефаропластика) в предоперационном периоде не менее чем за 3 года после косметологического воздействия в периорбитальной области. Вторая группа контрольная — 32 пациента без факторов риска развития в виде косметологического воздействия в периорбитальной зоне в предоперационном периоде. Первая группа была разделена на 3 подгруппы в зависимости от вида подготовки пациента к оперативному вмешательству: 1А (основная группа) — 30 пациентов: слезозаместительная терапия без комплексной терапии (гигиена век по разработанной методике + массаж в периорбитальной зоне), 1Б — 29 пациентов: слезозаместительная терапия + комплексная терапия по разработанной методике; 1В – 26 пациентов: слезозаместительная терапия + комплексная терапия по стандартной методике. Как показало проведенное исследование, при наличии в предоперационном периоде у пациентов перед факоэмульсификацией факторов риска развития ССГ, включая косметологическое воздействие в периорбитальной зоне в анамнезе, отмечено повышение риска развития тяжелой формы синдрома сухого глаза и воспалительного процесса в раннем послеоперационном периоде на сроке наблюдения 2 недели. Данной группе пациентов рекомендовано проводить комплекс лечебных физиотерапевтических процедур — гигиена век + массаж в периорбитальной зоне, направленных на восстановление функциональной активности мейбомиевых желез и повышение стабильности слезной пленки, что снижает частоту возникновения тяжелой формы ССГ и воспалительного процесса в послеоперационном периоде после проведения факоэмульсификации катаракты на 19,89 %.</p></abstract><trans-abstract xml:lang="en"><p>Phacoemulsification of cataracts in modern ophthalmological practice has reached its peak in terms of safety, predictability of the result and patient satisfaction with the result obtained. The effect of dry eye syndrome on the effectiveness of this surgical intervention has been studied to a large extent, but new risk factors affecting the development of dry eye syndrome arise, such as cosmetic intervention in the periorbital zone (botulinum toxin injections in the periorbital zone, eyelash extensions, blepharoplasty). The effect of these risk factors for the development of dry eye syndrome (DES) on the course of the postoperative period has not been sufficiently studied. An important aspect in preparing patients for ophthalmic surgery, in particular, for phacoemulsification of cataracts, which has moved into the category of, among other things, refractive surgeries, is stabilization of the ocular surface and relief of signs and symptoms of DES.</p><p>Materials and methods. The study included 117 patients who were planned to undergo phacoemulsification of cataracts. All 117 patients were female for the unification of the study. The first group included 85 people with risk factors for developed dry eye syndrome (botox, tattooing, eyelash extensions, blepharoplasty) in the preoperative period of at least 3 years after cosmetology intervention in the periorbital area. The second control group included 32 patients without risk factors for development in the form of cosmetology intervention in the periorbital area in the preoperative period. The first group was divided into 3 subgroups depending on the type of patient preparation for surgery: 1A (main group) — 30 patients: tear replacement therapy without complex therapy (eyelid hygiene according to the developed technique + massage in the periorbital area), 1B — 29 patients: tear replacement therapy + complex therapy according to the developed technique; 1B — 26 patients: tear replacement therapy + complex therapy according to the standard technique. As the study showed, in the presence of risk factors for the development of dry eye syndrome in the preoperative period before phacoemulsification, including a history of cosmetic interventions in the periorbital area, an increased risk of developing a severe form of dry eye syndrome and an inflammatory process in the early postoperative period was noted at a 2-week observation period. This group of patients is recommended to undergo a set of therapeutic physiotherapeutic procedures — eyelid hygiene + massage in the periorbital area, aimed at restoring the functional activity of the meibomian glands and increasing the stability of the tear film, which reduces the incidence of severe dry eye syndrome and inflammation in the postoperative period after cataract phacoemulsification by 19.89%.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>офтальмология</kwd><kwd>факоэмульсификация</kwd><kwd>катаракта</kwd><kwd>синдром сухого глаза</kwd><kwd>глазная поверхность</kwd><kwd>диагностика синдрома сухого глаза</kwd><kwd>косметология</kwd></kwd-group><kwd-group xml:lang="en"><kwd>ophthalmology</kwd><kwd>phacoemulsification</kwd><kwd>cataract</kwd><kwd>dry eye syndrome</kwd><kwd>ocular surface</kwd><kwd>diagnosis of dry eye syndrome</kwd><kwd>cosmetology</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Donaldson K, Parkhurst G, Saenz B, Whitley W, Williamson B, Hovanesian J. Call to action: treating dry eye disease and setting the foundation for successful surgery. J Cataract Refract Surg. 2022 May 1;48(5):623‑629. doi: 10.1097/j.jcrs.0000000000000844.</mixed-citation><mixed-citation xml:lang="en">Donaldson K, Parkhurst G, Saenz B, Whitley W, Williamson B, Hovanesian J. Call to action: treating dry eye disease and setting the foundation for successful surgery. J Cataract Refract Surg. 2022 May 1;48(5):623‑629. doi: 10.1097/j.jcrs.0000000000000844.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Jones L, Downie LE, Korb D, TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575–628. doi: 10.1016/j.jtos.2017.05.006.</mixed-citation><mixed-citation xml:lang="en">Jones L, Downie LE, Korb D, TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575–628. doi: 10.1016/j.jtos.2017.05.006.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Chuang J, Shih KC, Chan TC, Wan KH, Jhanji V, Tong L. Preoperative optimization of ocular surface disease before cataract surgery. J Cataract Refract Surg. 2017;43(12):1596–1607. doi: 10.1016/j.jcrs.2017.10.033.</mixed-citation><mixed-citation xml:lang="en">Chuang J, Shih KC, Chan TC, Wan KH, Jhanji V, Tong L. Preoperative optimization of ocular surface disease before cataract surgery. J Cataract Refract Surg. 2017;43(12):1596–1607. doi: 10.1016/j.jcrs.2017.10.033.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Starr CE, Gupta PK, Farid M, ASCRS Cornea Clinical Committee. An algorithm for the preoperative diagnosis and treatment of ocular surface disorders. J Cataract Refract Surg. 2019;45(5):669–684. doi: 10.1016/j.jcrs.2019.03.023.</mixed-citation><mixed-citation xml:lang="en">Starr CE, Gupta PK, Farid M, ASCRS Cornea Clinical Committee. An algorithm for the preoperative diagnosis and treatment of ocular surface disorders. J Cataract Refract Surg. 2019;45(5):669–684. doi: 10.1016/j.jcrs.2019.03.023.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Трубилин ВН, Полунина ЕГ, Анджелова ДВ, Куренков ВВ, Капкова СГ, Чиненова КВ, Коновалов МЕ, Пожарицкий МД. Современные представления об этиологии синдрома сухого глаза. Офтальмология. 2019;16(2):236–243. doi: 10.18008/1816‑5095‑2019‑2‑236‑243.</mixed-citation><mixed-citation xml:lang="en">Trubilin VN, Polunina EG, Angelova DV, Kurenkov VV, Kapkova SG, Chinenova KV, Konovalov ME, Pozharitsky MD. Current Concepts about the Etiology of Dry Eye Syndrome. Ophthalmology in Russia. 2019;16(2):236–243 (In Russ.). doi: 10.18008/1816‑5095‑2019‑2‑236‑243.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015 Jan 30;112(5):71–81; quiz 82. doi: 10.3238/arztebl.2015.0071.</mixed-citation><mixed-citation xml:lang="en">Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015 Jan 30;112(5):71–81; quiz 82. doi: 10.3238/arztebl.2015.0071.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Cutolo CA, Barabino S, Bonzano C, Traverso CE. The Use of Topical Corticosteroids for Treatment of Dry Eye Syndrome. Ocul Immunol Inflamm. 2019;27(2):266– 275. doi: 10.1080/09273948.2017.1341988.</mixed-citation><mixed-citation xml:lang="en">Cutolo CA, Barabino S, Bonzano C, Traverso CE. The Use of Topical Corticosteroids for Treatment of Dry Eye Syndrome. Ocul Immunol Inflamm. 2019;27(2):266– 275. doi: 10.1080/09273948.2017.1341988.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Pleyer U, Geerling G, Schrader S, Jacobi C, Kimmich F, Messmer E. Wenn Tränenersatzmittel nicht mehr ausreichen: die Bedeutung von Entzündungsprozessen beim Trockenen Auge. Praktische Aspekte einer antientzündlichen Therapie des Trockenen Auges [If Artificial Tears Aren’t Enough. The Importance of Inflammatory Processes in Dry Eye Disease. Practical Aspects of an Anti‑Inflammatory Therapy of Dry Eye Disease]. Klin Monbl Augenheilkd. 2020 May;237(5):655–668. German. doi: 10.1055/a‑1115‑4756.</mixed-citation><mixed-citation xml:lang="en">Pleyer U, Geerling G, Schrader S, Jacobi C, Kimmich F, Messmer E. Wenn Tränenersatzmittel nicht mehr ausreichen: die Bedeutung von Entzündungsprozessen beim Trockenen Auge. Praktische Aspekte einer antientzündlichen Therapie des Trockenen Auges [If Artificial Tears Aren’t Enough. The Importance of Inflammatory Processes in Dry Eye Disease. Practical Aspects of an Anti‑Inflammatory Therapy of Dry Eye Disease]. Klin Monbl Augenheilkd. 2020 May;237(5):655–668. German. doi: 10.1055/a‑1115‑4756.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Трубилин ВН, Полунина ЕГ, Трубилин АВ, Куренков ВВ, Коновалов МЕ, Закатянский ВС. Диагностика синдрома сухого глаза при подготовке пациентов к факоэмульсификации катаракты. Обзор литературы. Офтальмология. 2024;21(2):248–255. doi: 10.18008/1816‑5095‑2024‑2‑248‑255.</mixed-citation><mixed-citation xml:lang="en">Trubilin VN, Polunina EG, Trubilin AV, Kurenkov VV, Konovalov ME, Zakatianskiy VS. Diagnosis of Dry Eye Syndrome During the Preparing Patients for Cataracts Phacoemulsification. Literature Review. Ophthalmology in Russia. 2024;21(2):248– 255 (In Russ.). doi: 10.18008/1816‑5095‑2024‑2‑248‑255.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Donthineni PR, Das AV, Shanbhag SS, Basu S. Cataract Surgery in Dry Eye Disease: Visual Outcomes and Complications. Front Med (Lausanne). 2020 Oct 7;7:575834. doi: 10.3389/fmed.2020.575834.</mixed-citation><mixed-citation xml:lang="en">Donthineni PR, Das AV, Shanbhag SS, Basu S. Cataract Surgery in Dry Eye Disease: Visual Outcomes and Complications. Front Med (Lausanne). 2020 Oct 7;7:575834. doi: 10.3389/fmed.2020.575834.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wolf EJ, Kleiman LZ, Schrier A. Nepafenac‑associated corneal melt. J Cataract Refract Surg. 2007 Nov;33(11):1974–1975. doi: 10.1016/j.jcrs.2007.06.043.</mixed-citation><mixed-citation xml:lang="en">Wolf EJ, Kleiman LZ, Schrier A. Nepafenac‑associated corneal melt. J Cataract Refract Surg. 2007 Nov;33(11):1974–1975. doi: 10.1016/j.jcrs.2007.06.043.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Koh S, Inoue Y, Sugmimoto T, Maeda N, Nishida K. Effect of rebamipide ophthalmic suspension on optical quality in the short break‑up time type of dry eye. Cornea. 2013 Sep;32(9):1219–1223. doi: 10.1097/ICO.0b013e318294f97e.</mixed-citation><mixed-citation xml:lang="en">Koh S, Inoue Y, Sugmimoto T, Maeda N, Nishida K. Effect of rebamipide ophthalmic suspension on optical quality in the short break‑up time type of dry eye. Cornea. 2013 Sep;32(9):1219–1223. doi: 10.1097/ICO.0b013e318294f97e.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Baudouin C, Aragona P, Messmer EM, Tomlinson A, Calonge M, Boboridis KG, Akova YA, Geerling G, Labetoulle M, Rolando M. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf. 2013 Oct;11(4):246–258. doi: 10.1016/j.jtos.2013.07.003. Epub 2013 Aug 9. PMID: 24112228.</mixed-citation><mixed-citation xml:lang="en">Baudouin C, Aragona P, Messmer EM, Tomlinson A, Calonge M, Boboridis KG, Akova YA, Geerling G, Labetoulle M, Rolando M. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf. 2013 Oct;11(4):246–258. doi: 10.1016/j.jtos.2013.07.003. Epub 2013 Aug 9. PMID: 24112228.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Barabino S, Benitez‑Del‑Castillo JM, Fuchsluger T, Labetoulle M, Malachkova N, Meloni M, Utheim TP, Rolando M. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification. Eur Rev Med Pharmacol Sci. 2020 Sep;24(17):8642–8652. doi: 10.26355/eurrev_202009_22801. PMID: 32964952.</mixed-citation><mixed-citation xml:lang="en">Barabino S, Benitez‑Del‑Castillo JM, Fuchsluger T, Labetoulle M, Malachkova N, Meloni M, Utheim TP, Rolando M. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification. Eur Rev Med Pharmacol Sci. 2020 Sep;24(17):8642–8652. doi: 10.26355/eurrev_202009_22801. PMID: 32964952.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Cagini C, Di Lascio G, Torroni G, Mariniello M, Meschini G, Lupidi M, Messina M. Dry eye and inflammation of the ocular surface after cataract surgery: effectiveness of a tear film substitute based on trehalose/hyaluronic acid vs hyaluronic acid to resolve signs and symptoms. J Cataract Refract Surg. 2021 Nov 1;47(11):1430–1435. doi: 10.1097/j.jcrs.0000000000000652.</mixed-citation><mixed-citation xml:lang="en">Cagini C, Di Lascio G, Torroni G, Mariniello M, Meschini G, Lupidi M, Messina M. Dry eye and inflammation of the ocular surface after cataract surgery: effectiveness of a tear film substitute based on trehalose/hyaluronic acid vs hyaluronic acid to resolve signs and symptoms. J Cataract Refract Surg. 2021 Nov 1;47(11):1430–1435. doi: 10.1097/j.jcrs.0000000000000652.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kim M, Lee Y, Mehra D, Sabater AL, Galor A. Dry eye: why artificial tears are not always the answer. BMJ Open Ophthalmol. 2021 Apr 8;6(1):e000697. doi: 10.1136/bmjophth‑2020‑000697. PMID: 33907713;</mixed-citation><mixed-citation xml:lang="en">Kim M, Lee Y, Mehra D, Sabater AL, Galor A. Dry eye: why artificial tears are not always the answer. BMJ Open Ophthalmol. 2021 Apr 8;6(1):e000697. doi: 10.1136/bmjophth‑2020‑000697. PMID: 33907713;</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Daull P, Amrane M, Ismail D, Georgiev G, Cwiklik L, Baudouin C, Leonardi A, Garhofer G, Garrigue JS. Cationic Emulsion‑Based Artificial Tears as a Mimic of Functional Healthy Tear Film for Restoration of Ocular Surface Homeostasis in Dry Eye Disease. J Ocul Pharmacol Ther. 2020 Jul/Aug;36(6):355–365. doi: 10.1089/jop.2020.0011.</mixed-citation><mixed-citation xml:lang="en">Daull P, Amrane M, Ismail D, Georgiev G, Cwiklik L, Baudouin C, Leonardi A, Garhofer G, Garrigue JS. Cationic Emulsion‑Based Artificial Tears as a Mimic of Functional Healthy Tear Film for Restoration of Ocular Surface Homeostasis in Dry Eye Disease. J Ocul Pharmacol Ther. 2020 Jul/Aug;36(6):355–365. doi: 10.1089/jop.2020.0011.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Donthineni PR, Shanbhag SS, Basu S. An Evidence‑Based Strategic Approach to Prevention and Treatment of Dry Eye Disease, a Modern Global Epidemic. Healthcare (Basel). 2021 Jan 17;9(1):89. doi: 10.3390/healthcare9010089.</mixed-citation><mixed-citation xml:lang="en">Donthineni PR, Shanbhag SS, Basu S. An Evidence‑Based Strategic Approach to Prevention and Treatment of Dry Eye Disease, a Modern Global Epidemic. Healthcare (Basel). 2021 Jan 17;9(1):89. doi: 10.3390/healthcare9010089.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Sánchez MA, Arriola‑Villalobos P, Torralbo‑Jiménez P, Girón N, de la Heras B, Herrero Vanrell R, Alvarez‑Barrientos A, Benítez‑del‑Castillo JM. The effect of preservative‑free HP‑Guar on dry eye after phacoemulsification: a flow cytometric study. Eye (Lond). 2010 Aug;24(8):1331–1337. doi: 10.1038/eye.2010.24.</mixed-citation><mixed-citation xml:lang="en">Sánchez MA, Arriola‑Villalobos P, Torralbo‑Jiménez P, Girón N, de la Heras B, Herrero Vanrell R, Alvarez‑Barrientos A, Benítez‑del‑Castillo JM. The effect of preservative‑free HP‑Guar on dry eye after phacoemulsification: a flow cytometric study. Eye (Lond). 2010 Aug;24(8):1331–1337. doi: 10.1038/eye.2010.24.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Rossi GCM, Tinelli C, Milano G, Lanteri S, Ricciarelli G, Giannì L, Pasinetti GM, Scudeller L. Randomised, Single Blind, Controlled, Three‑Month Clinical Trial on the Evaluation and Treatment of the Ocular Surface Damage Following Phacoemulsification. Vision (Basel). 2022 Jul 6;6(3):42. doi: 10.3390/vision6030042.</mixed-citation><mixed-citation xml:lang="en">Rossi GCM, Tinelli C, Milano G, Lanteri S, Ricciarelli G, Giannì L, Pasinetti GM, Scudeller L. Randomised, Single Blind, Controlled, Three‑Month Clinical Trial on the Evaluation and Treatment of the Ocular Surface Damage Following Phacoemulsification. Vision (Basel). 2022 Jul 6;6(3):42. doi: 10.3390/vision6030042.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Naderi K, Gormley J, O’Brart D. Cataract surgery and dry eye disease: A review. Eur J Ophthalmol. 2020 Sep;30(5):840–855. doi: 10.1177/1120672120929958.</mixed-citation><mixed-citation xml:lang="en">Naderi K, Gormley J, O’Brart D. Cataract surgery and dry eye disease: A review. Eur J Ophthalmol. 2020 Sep;30(5):840–855. doi: 10.1177/1120672120929958.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Pels E, Vrensen GF. Microbial decontamination of human donor eyes with povidoneiodine: penetration, toxicity, and effectiveness. Br J Ophthalmol. 1999 Sep;83(9):1019– 1026. doi: 10.1136/bjo.83.9.1019.</mixed-citation><mixed-citation xml:lang="en">Pels E, Vrensen GF. Microbial decontamination of human donor eyes with povidoneiodine: penetration, toxicity, and effectiveness. Br J Ophthalmol. 1999 Sep;83(9):1019– 1026. doi: 10.1136/bjo.83.9.1019.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Moreira LB, Kasetsuwan N, Sanchez D, Shah SS, LaBree L, McDonnell PJ. Toxicity of topical anesthetic agents to human keratocytes in vivo. J Cataract Refract Surg. 1999 Jul;25(7):975–980. doi: 10.1016/s0886‑3350(99)00075‑9.</mixed-citation><mixed-citation xml:lang="en">Moreira LB, Kasetsuwan N, Sanchez D, Shah SS, LaBree L, McDonnell PJ. Toxicity of topical anesthetic agents to human keratocytes in vivo. J Cataract Refract Surg. 1999 Jul;25(7):975–980. doi: 10.1016/s0886‑3350(99)00075‑9.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">He Y, Li J, Zhu J, Jie Y, Wang N, Wang J. The improvement of dry eye after cataract surgery by intraoperative using ophthalmic viscosurgical devices on the surface of cornea: The results of a consort‑compliant randomized controlled trial. Medicine (Baltimore). 2017 Dec;96(50):e8940. doi: 10.1097/MD.0000000000008940.</mixed-citation><mixed-citation xml:lang="en">He Y, Li J, Zhu J, Jie Y, Wang N, Wang J. The improvement of dry eye after cataract surgery by intraoperative using ophthalmic viscosurgical devices on the surface of cornea: The results of a consort‑compliant randomized controlled trial. Medicine (Baltimore). 2017 Dec;96(50):e8940. doi: 10.1097/MD.0000000000008940.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Choi YJ, Park SY, Jun I, Choi M, Seo KY, Kim EK, Kim TI. Perioperative Ocular Parameters Associated With Persistent Dry Eye Symptoms After Cataract Surgery. Cornea. 2018 Jun;37(6):734–739. doi: 10.1097/ICO.0000000000001572.</mixed-citation><mixed-citation xml:lang="en">Choi YJ, Park SY, Jun I, Choi M, Seo KY, Kim EK, Kim TI. Perioperative Ocular Parameters Associated With Persistent Dry Eye Symptoms After Cataract Surgery. Cornea. 2018 Jun;37(6):734–739. doi: 10.1097/ICO.0000000000001572.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Shivitz IA, Arrowsmith PN. Corneal sensitivity after radial keratotomy. Ophthalmology. 1988 Jun;95(6):827–832. doi: 10.1016/s0161‑6420(88)33102‑7.</mixed-citation><mixed-citation xml:lang="en">Shivitz IA, Arrowsmith PN. Corneal sensitivity after radial keratotomy. Ophthalmology. 1988 Jun;95(6):827–832. doi: 10.1016/s0161‑6420(88)33102‑7.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Matossian C. Impact of thermal pulsation treatment on astigmatism management and outcomes in meibomian gland dysfunction patients undergoing cataract surgery. Clin Ophthalmol Auckl NZ. 2020;14:2283–2289. doi: 10.2147/OPTH. S263046.</mixed-citation><mixed-citation xml:lang="en">Matossian C. Impact of thermal pulsation treatment on astigmatism management and outcomes in meibomian gland dysfunction patients undergoing cataract surgery. Clin Ophthalmol Auckl NZ. 2020;14:2283–2289. doi: 10.2147/OPTH. S263046.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Куренков ВВ, Жемчугова АВ, Полунина ЕГ, Абрамов СИ, Кожухов АА. Роль предоперационной терапевтической гигиены век в профилактике осложнений после эксимерлазерных операций. Офтальмология. 2012;9(3):86–92. doi: 10.18008/1816‑5095‑2012‑3‑86‑92. doi: 10.18008/1816‑5095‑2012‑3‑86‑92.</mixed-citation><mixed-citation xml:lang="en">Kurenkov VV, Zhemchugova AV, Polunina EG, Abramov SI, Kozhuchov AA. Preoperative therapeutic eyelid hygiene in the prevention of complications following excimer laser vision correction. Ophthalmology in Russia. 2012;9(3):86–92 (In Russ.). doi: 10.18008/1816‑5095‑2012‑3‑86‑92.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Медведев ИБ, Трубилин ВН, Полунина ЕГ, Дергачева НН, Анджелова ДВ, Евстигнеева ЮВ, Чиненова КВ. Влияние различных видов лечения дисфункции мейбомиевых желез, включая массаж в периорбитальной зоне, на гемодинамические показатели век. Офтальмология. 2022;19(2):359–367. doi: 10.18008/18165095‑2022‑2‑359‑367.</mixed-citation><mixed-citation xml:lang="en">Medvedev IB, Trubilin VN, Poluninа EG, Dergacheva NN, Andzhelova DV, Evstigneeva YuV, Chinenova KV. Modern Ideas about Dysfunction of the Meibomian Glands. Ophthalmology in Russia. 2022;19(2):359–367 (In Russ.). doi: 10.18008/18165095‑2022‑2‑359‑367.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Трубилин ВН, Полунина ЕГ, Кожухов АА, Анджелова ДВ, Трубилин АВ, Чиненова КВ, Морева НВ. Комплексная классификация степени выраженности бульбарной и тарзальной гиперемии при конъюнктивите. Офтальмология. 2023;20(3):471–478. doi: 10.18008/1816‑5095‑2023‑3‑471‑478.</mixed-citation><mixed-citation xml:lang="en">Trubilin VN, Polunina EG, Kozhukhov AA, Andzhelova DV, Trubilin AV, Chinenova KV, Moreva NV. Comprehensive Classification of the Severity of Bulbar and Tarsal Hyperemia in Conjunctivitis. Ophthalmology in Russia. 2023;20(3):471–478 (In Russ.). doi: 10.18008/1816‑5095‑2023‑3‑471‑478.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Трубилин ВН, Полунина ЕГ, Кожухов АА, Куренков ВВ, Морева НВ, Трубилин АВ, Чиненова КВ. Дифференциально‑диагностические показатели для назначения нестероидной противовоспалительной терапии в лечении синдрома красного глаза на этапе первичного амбулаторно‑поликлинического приема. Часть 1. Офтальмология. 2023;20(2):332–340. doi: 10.18008/1816‑5095‑2023‑2‑332‑340.</mixed-citation><mixed-citation xml:lang="en">Trubilin VN, Poluninа EG, Kozhukhov AA, Kurenkov VV, Moreva NV, Trubilin AV, Chinenova KV. Differential Diagnostic Indicators for the Appointment of NonSteroidal Anti‑Inflammatory Therapy in the Treatment of Red Eye Syndrome at the Stage of Primary Outpatient Admission. Part 1. Ophthalmology in Russia. 2023;20(2):332–340 (In Russ.). doi: 10.18008/1816‑5095‑2023‑2‑332‑340.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
